BackCytoMed Therapeutics Overview

CytoMed Therapeutics Current Cash

Track CytoMed Therapeutics's current cash ($2.1M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$2.10M
↓ 39.14% YoYΔ $-1.35M vs prior year quarter

Peer average

Loading

CytoMed Therapeutics Current Cash History

Loading

CytoMed Therapeutics vs. peers: Current Cash Comparison

Loading

CytoMed Therapeutics Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

CytoMed Therapeutics (GDTC) FAQ

CytoMed Therapeutics posts a current cash of $2.1M as of December 2025. That compares with $3.4M in the prior-year period — down 39.1% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, CytoMed Therapeutics's current cash was $3.4M. The latest reading is $2.1M — a 39.1% year-over-year decrease (period ending December 2025). Use the history and growth charts on this page for a longer lookback.

Current Cash is one piece of CytoMed Therapeutics's financial statement story. At $2.1M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for GDTC's current cash usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; CytoMed Therapeutics's other metric pages and overview cover the third.